China Approves HERNEXEOS® As First Targeted Oral Treatment Option For HER2-Mutant Advanced NSCLC At Initial Diagnosis

(MENAFN - GlobeNewsWire - Nasdaq) Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in ...